Q-omics provides the consensus-scored MAFB profile across patient tissues and cancer cell-line models. MAFB expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MAFB is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, MAFB RNA expression shows 19,829 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, THCA, and GBM as cancer lineages where MAFB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAFB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAFB survival associations across molecular data types. MAFB RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAFB RNA expression–survival associations across cancer types. High MAFB expression shows unfavorable associations in UVM, LAML and ACC, but favorable associations in SKCM, ESCA and LGG. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MAFB RNA expression.
This table summarizes MAFB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MAFB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAFB shows lower tumor expression in THCA, CHOL and COAD and higher tumor expression in KIRC and HNSC. The THCA box plot shows higher MAFB RNA expression in normal versus tumor tissue (log2 FC = −2.532, t-test p < 0.001).
This table shows molecular features associated with MAFB in patient tissues and cancer cell lines. In patient samples, MAFB shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAFB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and SOFT_TISSUE.
